Kristen A. Marrone, MD

home / authors / kristen-marrone-md

Articles

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD;Yoon-Koo Kang, MD, PhD;Hope E. Uronis, MD, MHS;Keun-Wook Lee, MD, PhD;Matthew C. H. Ng, MD;Peter C. Enzinger, MD;Se Hoon Park, MD, PhD;Philip J. Gold, MD;Jill Lacy, MD;Howard S. Hochster, MD;Sang Cheul Oh, MD, PhD;Yeul Hong Kim, MD, PhD;Kristen A. Marrone, MD;Ronan J. Kelly, MD;Rosalyn A. Juergens, MD;Jong Gwang Kim, MD, PhD;Thierry Alcindor, MD, MSc;Sun Jin Sym, MD, PhD;Eun-Kee Song, MD, PhD;Cheng Ean Chee, MD;Yee Chao, MD, PhD;Sunnie Kim, MD;Do-Youn Oh, MD, PhD;Jennifer Yen, PhD;Justin I. Odegaard, MD, PhD;Errin Lagow, PhD;Daner Li, MS;Jichao Sun, PhD;Patrick Kaminker, PhD;Paul A. Moore, PhD;Minori Koshiji Rosales, MD, PhD;Haeseong Park, MD, MPH
April 27th 2023

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Using Immune Checkpoint Inhibitors in Lung Cancer

Using Immune Checkpoint Inhibitors in Lung Cancer

Kristen A. Marrone, MD;Julie R. Brahmer, MD
August 16th 2016

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
NSCLC Patient Develops Fever and Rash Following Treatment for Brain Metastases
Published: July 31st 2012 | Updated: July 4th 2025
NSCLC Patient Develops Fever and Rash Following Treatment for Brain Metastases